ECEmmanuelle Cambau

Emmanuelle Cambau

*This is an algorithmically generated author record based on publicly available information.

Emmanuelle Cambau has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Christine Lascols

    Université Paris 12, Créteil, F-94000, France,1 AP-HP, Hôpital Henri-Mondor, Laboratoire de Bactériologie-Virologie-Hygiène, Créteil, F-94000, France,2 Hain Lifesciences, Nehren, Germany,3 AP-HP, Hôpital Henri-Mondor, Service d'Hépato-Gastroentérologie, Créteil, F-94000, France,4 Centre National de Référence des Campylobacter et Helicobacter, Université Victor Segalen Bordeaux 2, Bordeaux, France,5 INSERM U853, 33076 Bordeaux Cedex, France6

    3 shared publications
  • Vincent Jarlier

    Service de Bactériologie et Hygiène, Centre National de Référence de la Résistance des Mycobactéries aux Antituberculeux, Pitié-Salpêtrière, Paris, France Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgique

    3 shared publications
  • Alexandra Aubry

    Université Pierre et Marie Curie-Paris 6, EA1541 Paris, France

    2 shared publications
  • C Truffot-Pernot

    2 shared publications
  • Claude-James Soussy

    Université Paris 12, Créteil, F-94000, France,1 AP-HP, Hôpital Henri-Mondor, Laboratoire de Bactériologie-Virologie-Hygiène, Créteil, F-94000, France,2 Hain Lifesciences, Nehren, Germany,3 AP-HP, Hôpital Henri-Mondor, Service d'Hépato-Gastroentérologie, Créteil, F-94000, France,4 Centre National de Référence des Campylobacter et Helicobacter, Université Victor Segalen Bordeaux 2, Bordeaux, France,5 INSERM U853, 33076 Bordeaux Cedex, France6

    2 shared publications
  • Céline Corbel

    Université Paris 12, Créteil, F-94000, France,1 AP-HP, Hôpital Henri-Mondor, Laboratoire de Bactériologie-Virologie-Hygiène, Créteil, F-94000, France,2 Hain Lifesciences, Nehren, Germany,3 AP-HP, Hôpital Henri-Mondor, Service d'Hépato-Gastroentérologie, Créteil, F-94000, France,4 Centre National de Référence des Campylobacter et Helicobacter, Université Victor Segalen Bordeaux 2, Bordeaux, France,5 INSERM U853, 33076 Bordeaux Cedex, France6

    2 shared publications

Latest Publications

  • Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm (41) and rrl Sequencing

    by Sylvaine Bastian, Nicolas Veziris, Anne-Laure Roux, Florence Brossier, Jean-Louis Gaillard, Vincent Jarlier, Emmanuelle Cambau

    Clarithromycin was the drug of choice for Mycobacterium abscessus infections until inducible resistance due to erm (41) was described. Because M. abscessus was split into M. abscessus sensu stricto, Mycobacterium massiliense , and Mycobacterium bolletii , we looked for erm (41) in the three species and determined their clarithromycin susceptibility levels. Ninety strains were included: 87 clinical strains from cystic fibrosis patients (61%) and others (39%), representing 43 M. abscessus , 30 M. massiliense , and 14 M. bolletii strains identified on a molecular basis, and 3 reference strains. Clarithromycin and azithromycin MICs were determined by broth microdilution and Etest with a 14-day incubation period. Mutations in rrl (23S rRNA gene) known to confer acquired clarithromycin resistance were also sought. erm (41) was detected in all strains but with two deletions in all M. massiliense strains. These strains were indeed susceptible to clarithromycin (MIC 90 of 1 μg/ml) except for four strains with rrl mutations. M. abscessus strains harbored an intact erm (41) but had a T/C polymorphism at the 28th nucleotide: T28 strains (Trp10 codon) demonstrated inducible clarithromycin resistance (MIC 90 of >16 μg/ml), while C28 strains (Arg10) were susceptible (MIC 90 of 2 μg/ml) except for two strains with rrl mutations. M. bolletii strains had erm (41) sequences similar to the sequence of the T28 M. abscessus group, associated with inducible clarithromycin resistance (MIC 90 of >16 μg/ml). erm (41) sequences appeared species specific within the M. abscessus group and were fully concordant with clarithromycin susceptibility when erm (41) sequencing was associated with detection of rrl mutations. Clarithromycin-resistant strains, including the six rrl mutants, were more often isolated in cystic fibrosis patients, but this was not significantly associated with a previous treatment.


  • Open Access

    Evaluation of a New Test, GenoType HelicoDR, for Molecular Detection of Antibiotic Resistance inHelicobacter pylori

    by Emmanuelle Cambau, Vera Allerheiligen, Céline Coulon, Céline Corbel, Christine Lascols, Lionel Deforges, Claude-James Soussy, Jean-Charles Delchier, Francis Megraud

    The eradication rate ofHelicobacter pyloriby standard therapy is decreasing due to antibiotic resistance, mainly to clarithromycin. Our aim was to provide a new molecular test to guide the treatment of new and relapsed cases. We first studied 126H. pyloristrains for phenotypic (MIC) and genotypic resistance to clarithromycin (rrlmutation) and levofloxacin (gyrAmutation) and then developed a DNA strip genotyping test on the basis of the correlation results and literature data. Clinical strains (n= 92) and gastric biopsy specimens containingH. pylori(n= 105) were tested blindly with the new molecular test GenoType HelicoDR. The presence of mutations or the absence of hybridization with wild-type sequences was predictive, inrrlfor clarithromycin resistance in 91 cases (mostly the A2147G mutation) and ingyrAfor levofloxacin resistance in 58 cases (mutations at codon 87 or 91). Genotyping revealed a mix of genotypes in 33% of the cases, reflecting a coinfection or selection for resistant mutants. The sensitivity and specificity of detecting resistance were 94% and 99% for clarithromycin and 87% and 98.5% for levofloxacin, respectively. The concordance scores were 0.96 for clarithromycin and 0.94 for levofloxacin. With global resistance rates of 46% for clarithromycin and 25% for levofloxacin, which were observed for consecutive positive biopsy specimens from 2007 and 2008, the positive and negative predictive values for detecting resistance were 99% and 94% for clarithromycin and 96% and 96% for fluoroquinolone. GenoType HelicoDR is efficient at detecting mutations predictive of antibiotic resistance inH. pyloriwhen applied to strains or directly to gastric biopsy specimens.


  • The Pentapeptide Repeat Proteins MfpA Mt and QnrB4 Exhibit Opposite Effects on DNA Gyrase Catalytic Reactions and on the Ternary Gyrase-DNA-Quinolone Complex

    by Audrey MérEns, StépHanie Matrat, Alexandra Aubry, Christine Lascols, Vincent Jarlier, Claude-James Soussy, Jean-Didier Cavallo, Emmanuelle Cambau

    MfpA Mt and QnrB4 are two newly characterized pentapeptide repeat proteins (PRPs) that interact with DNA gyrase. The mfpA Mt gene is chromosome borne in Mycobacterium tuberculosis , while qnrB4 is plasmid borne in enterobacteria. We expressed and purified the two PRPs and compared their effects on DNA gyrase, taking into account host specificity, i.e., the effect of MfpA Mt on M. tuberculosis gyrase and the effect of QnrB4 on Escherichia coli gyrase. Whereas QnrB4 inhibited E. coli gyrase activity only at concentrations higher than 30 μM, MfpA Mt inhibited all catalytic reactions of the M. tuberculosis gyrase described for this enzyme (supercoiling, cleavage, relaxation, and decatenation) with a 50% inhibitory concentration of 2 μM. We showed that the D87 residue in GyrA has a major role in the MfpA Mt -gyrase interaction, as D87H and D87G substitutions abolished MfpA Mt inhibition of M. tuberculosis gyrase catalytic reactions, while A83S modification did not. Since MfpA Mt and QnrB4 have been involved in resistance to fluoroquinolones, we measured the inhibition of the quinolone effect in the presence of each PRP. QnrB4 reversed quinolone inhibition of E. coli gyrase at 0.1 μM as described for other Qnr proteins, but MfpA Mt did not modify M. tuberculosis gyrase inhibition by fluoroquinolones. Crossover experiments showed that MfpA Mt also inhibited E. coli gyrase function, while QnrB4 did not reverse quinolone inhibition of M. tuberculosis gyrase. In conclusion, our in vitro experiments showed that MfpA Mt and QnrB4 exhibit opposite effects on DNA gyrase and that these effects are protein and species specific.


  • Open Access

    Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli

    by Emmanuelle Cambau, Stephanie Matrat, Xiao-Su Pan, Romain Roth Dit Bettoni, Céline Corbel, Alexandra Aubry, Christine Lascols, Jean-Yves Driot, L. Mark Fisher

    Besifloxacin is a new fluoroquinolone in development for ocular use. We investigated its mode of action and resistance in two major ocular pathogens, Streptococcus pneumoniae and Staphylococcus aureus, and in the reference species Escherichia coli. Primary and secondary targets of besifloxacin were evaluated by: (i) mutant selection experiments; (ii) MIC testing of defined topoisomerase mutants; and (iii) inhibition and cleavable complex assays with purified S. pneumoniae and E. coli DNA gyrase and topoisomerase IV enzymes. Enzyme assays showed similar besifloxacin activity against S. pneumoniae gyrase and topoisomerase IV, with IC50 and CC25 of 2.5 and 1 µM, respectively. In contrast to ciprofloxacin and moxifloxacin, besifloxacin was equally potent against both S. pneumoniae and E. coli gyrases. DNA gyrase was the primary target in all three species, with substitutions observed at positions 81, 83 and 87 in GyrA and 426 and 466 in GyrB (E. coli numbering). Topoisomerase IV was the secondary target. Notably, resistant mutants were not recovered at 4-fold besifloxacin MICs for S. aureus and S. pneumoniae, and S. aureus topoisomerase mutants were only obtained after serial passage in liquid medium. Besifloxacin MICs were similarly affected by parC or gyrA mutations in S. aureus and S. pneumoniae and remained below 1 mg/L in gyrA–parC double mutants. Although mutant selection experiments indicated that gyrase is a primary target, further biochemical and genetic studies showed that besifloxacin has potent, relatively balanced activity against both essential DNA gyrase and topoisomerase IV targets in S. aureus and S. pneumoniae.


    • 1 June 2000
      • Vol. 4  (6) , 504-12

    Twenty-five years of tuberculosis in a French university hospital: a laboratory perspective.

    by J Robert, D Trystram, C Truffot-Pernot, E Cambau, V Jarlier, J Grosset

    To determine the impact of recent changes in the epidemiology of tuberculosis in France and other industrialised countries on the primary trends of tuberculosis case rates in a French university hospital. Descriptive study of all 4549 culture-positive tuberculosis cases hospitalised at Pitié-Salpêtrière Hospital between 1972 and 1996. From 1972, there was a decline of 5% per year in the tuberculosis case rate, which levelled off in 1983. The proportion of tuberculosis patients who were human immunodeficiency virus (HIV) positive increased from 2% in 1983 to 28% in 1990, and thereafter remained stable. The proportion of foreign-born tuberculosis patients also increased, from 40% in 1972 to 55% in 1985. These two changes affected drug resistance patterns. Drug resistance was more common among foreign-born than among French-born patients, whether previously treated or not. Resistance to rifampicin and multidrug resistance among previously untreated patients was highly related to HIV co-infection. Extrapulmonary sites of tuberculosis were more often smear-positive in HIV-positive than in non-HIV-positive patients (22.8% vs 12.6%), and bacteraemia was diagnosed almost exclusively in HIV-positive patients. The changes in clinical and bacteriological tuberculosis patterns at the hospital level over the last 25 years have paralleled those observed at national and international level in industrialised countries, including a slowing in the decrease in the case rate, due in part to the HIV epidemic, a higher proportion of foreign-born patients and an increase in drug resistance.


    • 1 May 1998
      • Vol. 2  (5) , 390-6

    Use of DNA fingerprinting for primary surveillance of nosocomial tuberculosis in a large urban hospital: detection of outbreaks in homeless people and migrant workers.

    by N Lemaître, W Sougakoff, C Truffot-Pernot, E Cambau, J P Derenne, F Bricaire, J Grosset, V Jarlier

    A large urban teaching hospital in the southeast of Paris. Primary surveillance of nosocomial transmission of tuberculosis (TB) by systematic restriction fragment length polymorphism analysis (RFLP) of isolates (n = 161) recovered from smear-positive pulmonary TB patients identified from 1 March 1993 to 28 February 1994, and from all TB patients (with any form of tuberculous infection) identified from 1 March 1994 to 30 April 1995. Systematic RFLP analysis revealed 12 clusters of patients (n = 40) infected by strains of Mycobacterium tuberculosis showing matching RFLP patterns. None of the isolates were multidrug-resistant. Compared with non-clustered patients, clustered patients were more likely to be homeless (55% vs 19%, P < or = 0.001), or Africans living in hostels for migrant workers (20% vs 6%, P = 0.01), and had fewer previous admissions to hospital (12% vs 28%, P = 0.05). Further epidemiological investigations showed that the clustered TB cases actually resulted not from nosocomial transmission, but from transmission in the community, very likely in homeless shelters and hostels for migrant workers. No nosocomial transmission of TB was identified among the patients included during the study period. Systematic RFLP analysis using hospital-based sampling can detect the spread of TB in specific environments in the community where transmission is occurring.


    • 5 April 1997
      • Vol. 26  (11) , 513

    [Generalized Mycobacterium avium complex infections in patients with HIV infection: a decreasing incidence].

    by E Cambau, M Jouan, V Jarlier, F Bricaire